Cargando…
BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E)
Abnormal RAS/RAF signaling plays a critical role in glioma. Although it is known that the V600E mutation of v-raf murine viral oncogene homolog B1 (BRAF (V600E)) and BRAF amplification (BRAF (AMP)) both result in constitutive activation of the RAS/RAF pathway, whether BRAF (V600E) and BRAF (AMP) hav...
Autores principales: | Da, Rong, Wang, Maode, Jiang, Haitao, Wang, Tuo, Wang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817544/ https://www.ncbi.nlm.nih.gov/pubmed/33489866 http://dx.doi.org/10.3389/fonc.2020.531968 |
Ejemplares similares
-
BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021) -
Composite pheochromocytoma/paraganglioma-ganglioneuroma: analysis of SDH and ATRX status, and identification of frequent HRAS and BRAF mutations
por: Chen, Jingci, et al.
Publicado: (2021) -
Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013) -
Optimal treatment strategy for metastatic melanoma patients harboring
BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)